Selected References:
- Coppola D, et al. 2007. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf; 30(3):247-64.
- Damkier P and Videbech P. 2018. The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review. CNS Drugs 32:351-366.
- Ennis ZN and Damkier P. 2014. Pregnancy Exposure to Olanzapine, Quetiapine, Risperidone, Aripiprazole and Risk of Congenital Malformation. A Systemic Review. Basic & Clinical Pharmacology & Toxicology 116:315-320.
- Elstein Y, et al. 2004. Pregnancies in Gaucher disease: a 5 -year study. Am J Obstet Gynecol 190:435-441.
- Habermann F, et al. 2013. Atypical Antipsychotic Drugs and Pregnancy Outcome: A Prospective, Cohort Study. J Clin Psychopharmacol 33:453-62.
- Huybrechts KF, et al. 2016. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry 73(9): 938-946.
- McAllister-Williams RH, et al. 2017. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol; 31(5): 519-552.
- Park Y, et al. 2018. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. Am J Psychiatry 175(6):564-574.
- Petersen I, et al. 2016. Risks and Benefits of Psychotropic Medication in Pregnancy: Cohort Studies based on UK Electronic Primary Care Health Records. Health Technol Assess 20:1-176
- Uguz F. 2016. Second-Generation Antipsychotics During the Lactation Period. J Clin Psychopharmacol 36(3):244-252.
- Uguz F. 2019. Adverse events in a breastfed infant exposed to risperidone and haloperidol. Breastfeed Med.;14:683–4.
- Vigod SN, et al. 2015. Antipsychotic Drug Use In Pregnancy: High Dimensional, Propensity Matched, Population Based Cohort Study. BMJ 350:h2298.
